Pharmotech SA, is a Geneva based Swiss laboratory focused primarily on the phyto-research and development of pharmacological antibacterial applications of cannabidiol (CBD) on multidrug resistant (MDR) bacteria, with a specific focus on Pseudomonas aeruginosa. The Company is collaborating with academic research partners, University of Geneva (UNIGE) and Fribourg (UNIF) and the SICHH institute, to conduct multiple studies on the complicated pathologies of bacterial contamination and its eradication. Pharmotech SA intends to become a leading pharmaceutical player in the global production and distribution of cannabinoids (CBD) based medical products for antibacterial applications. Cannabidiol is one of the more than 85 cannabinoids so far identified in marijuana and hemp. Numerous studies have shown that CBD possesses an extraordinary array of therapeutic benefits, including antioxidant and neuroprotective properties. Cannabinoids are used in the formulation of numerous products marketed as nutritional supplements, herbal medicines, cosmetics, and therapeutics. Pharmotech has targeted CBD as an antibacterial topical application to prevent critical health issues caused by bacteria, which has become more antibiotic resistant over time. The Company’s preliminary research has recorded very promising outcomes in the development of an innovative, all-natural CBD based antibacterial formulation to prevent, and cure bacterial infections. This preliminary research has been positively backed by a in vivo study and a pre-clinical analysis recently performed at CHUV (Centre Hospitalaire Universitaire Vaudois). Before the end of 2018, the clinical trials required for Pharmotech’s technology to become a medical device will begin.